Findings

What do systematic reviews say?

120 questions · 121 findings · 63 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 11.6%GRADE not reported 4 · 3.3%Very low 30 · 24.8%Low 46 · 38%Moderate 22 · 18.2%High 5 · 4.1%

Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U

Total adverse events · glabellar lines

Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).

1 finding from 1 review

Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.54]
2 studies · 492 participants
Moderate

Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U

Total adverse events · glabellar lines

It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes total adverse events compared with onabotulinumtoxinA 24U (very low certainty).

1 finding from 1 review

Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
OR 0.02 [0, 1.77]
1 study · 381 participants
Very low

Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo

Total adverse events · glabellar lines

Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
RR 2.23 [1.46, 3.4]
2 studies · 716 participants
Moderate

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

Total adverse events · glabellar lines

Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).

1 finding from 1 review

Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
RR 1.14 [0.89, 1.45]
8 studies · 1388 participants
Low

Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo

Total adverse events · glabellar lines

Summary of Findings Table ‐ AbobotulinumtoxinA 50U may leads to higher total adverse events compared with placebo (low certainty).

1 finding from 1 review

Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
RR 1.25 [1.05, 1.49]
8 studies · 1471 participants
Low

D‐cycloserine vs placebo

Total adverse events · children aged 5 to 11 years with ASD

D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).

1 finding from 1 review

The effectiveness and adverse effects of D‐cycloserine compared with placebo on social and communication skills in… 2021 · Cochrane Headline outcomes only
RR 1.11 [0.94, 1.31]
1 study · 67 participants
Low

Combination inhaled therapy vs SABA

Total adverse events · Adults with acute asthma

Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).

1 finding from 1 review

Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma 2017 · Cochrane Headline outcomes only
OR 2.03 [1.28, 3.2]
11 studies · 1392 participants
Moderate

Benzbromarone vs probenecid

Total adverse events · people with chronic gout

Benzbromarone may leads to lower total adverse events compared with probenecid (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 0.43 [0.25, 0.74]
2 studies · 129 participants
Low

Benzbromarone vs allopurinol

Total adverse events · people with chronic gout

Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 3 [0.64, 14.16]
1 study · 55 participants
Low

Nefopam 60 mg tds vs placebo

Total adverse events · patients with pain management in rheumatoid arthritis

Nefopam 60 mg tds may leads to higher total adverse events compared with placebo (low certainty).

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
RR 4.11 [1.58, 10.69]
2 studies · 104 participants
Low

Oromucosal cannabis (Sativex) vs placebo

Total adverse events · patients with pain management in rheumatoid arthritis

Oromucosal cannabis (Sativex) may leads to higher total adverse events compared with placebo (low certainty).

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
RR 1.82 [1.1, 3]
1 study · 58 participants
Low

Teicoplanin vs vancomycin

Total adverse events · patients with proven or suspected infection

It is very uncertain whether teicoplanin changes total adverse events compared with vancomycin (very low certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 0.56 [0.33, 0.95]
11 studies · 880 participants
Very low

Skim milk enriched with GMP/G600 vs skim milk & lactose powder

Total adverse eventsd · people with chronic gout

Skim milk enriched with GMP/G600 showed no clear difference in total adverse eventsd compared with skim milk, plus lactose powder (low certainty).

1 finding from 1 review

Dietary supplements for chronic gout 2021 · Cochrane Headline outcomes only
RR 0.97 [0.66, 1.45]
1 study · 120 participants
Low

BM‐MSC vs no treatment

Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.86 [0.62, 1.19]
1 study · 64 participants
Low

Linezolid vs no linezolid

Total adverse eventsg · drug‐resistant pulmonary tuberculosis

1 finding from 1 review

Linezolid for drug‐resistant pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Very low

Intervention not reported

Total adverse events1 · people following primary uncemented THA

The review found no eligible studies for this question.

1 finding from 1 review

Assistive devices, hip precautions, environmental modifications and training to prevent dislocation and improve… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events (total): · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments

It is very uncertain whether the intervention changes adverse events (total): (very low certainty).

1 finding from 1 review

Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy 2020 · Cochrane Headline outcomes only
RR 0.5 [0.14, 1.74]
1 study · 42 participants
Very low

Intervention not reported

Total adverse events Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)

The intervention showed no clear difference in total adverse events Last (low certainty).

1 finding from 1 review

Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes only
RR 1.15 [0.78, 1.7]
9 studies · 1326 participants
Low

First‐line thiazides vs ACE inhibitor

Total serious adverse events · patients with hypertension

The review found no eligible studies for this question.

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

First‐line thiazides vs beta‐blocker

Total serious adverse events · patients with hypertension

The review found no eligible studies for this question.

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found